创新医疗技术控股公司（Creative Medical Technology Holdings, Inc.）在获得美国食品药品监督管理局（FDA）的新许可后，已着手扩大其Adapt临床试验的范围。与此同时，公司正迅速推进其核心候选产品Olastrocel用于治疗慢性下背痛的第三期临床试验规划。
此次监管进展为Adapt试验的扩展扫清了障碍，标志着公司在该治疗领域的研究迈出了关键一步。Olastrocel作为一种针对慢性疼痛的细胞疗法，其后续开发进程也因此获得显著加速。
公司管理层表示，快速向三期试验迈进是基于此前获得的积极数据与FDA的持续反馈。这一系列动作凸显了公司致力于解决慢性下背痛这一未满足巨大医疗需求的战略决心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.